Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-09-30

Clinical Trial Update: Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update on Nexavar-Tarceva combination as first-line therapy for hepatocellular carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)
  • Tarceva (erlotinib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2013-09-30